LSTA Company Profile and Key Details

LSTA has shown mixed momentum, gaining 3.85% over the past week and -11.48% over the past quarter, though year-to-date performance is up 16.13%. Short-term trend indicators are bearishly aligned (SMA20 -2.78%, SMA50 33.66%, SMA200 66.19%). The stock’s 14-day RSI is 67.54 (firm momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.85% below its high and over 143.65% above its low. Average 10-day trading volume of 55.86 thousand shares is below the 3-month average of 82.45 thousand, indicating normal recent market interest.

Lisata Therapeutics, Inc. generated EPS of -$2.13 over the past year. Five-year average earnings growth is 38.88%. Wall Street analysts project EPS growth of 34.97% annually over the next five years. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.51. Next year's EPS is expected at $7.73. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $15.00. The high target offers 925.64% upside. The low target suggests 380.77% downside. The mean target is $23.50. This offers 653.21% upside. Lisata Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 12, 2026, missed forecasts by -35.29%. The prior quarter beat by -9.26%. Over the last six quarters, Apple has recorded several small beats. These include -21.33% in November 12, 2024.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) closed at $3.13 USD, gaining $0.01 (0.32%) from the previous close of $3.12. The stock is currently mid-range between its 52-week high and low $1.81 and $5.07. With a market capitalization of about $28.27 million, Lisata Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 84.17 thousand shares, volume is running light vs its 52-week average. Headquartered in Basking Ridge, NJ, Lisata Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David J. Mazzo, the company employs approximately 26 people and listed since March 01, 1999. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue.

Lisata Therapeutics, Inc. has 8.60 million shares outstanding. The public float is 7.26 million shares, elevated short interest at 0.67% of float. This equals 47.90 thousand shares. The short ratio is 0.95 days. Institutional investors hold 11.15% of the float. Insiders own 19.82%.

Lisata Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.85. This means the shares are trading above this model’s fair value.

Lisata Therapeutics, Inc. trades at a P/E ratio of -1.63, slightly below the S&P 500 average, with a price-to-sales ratio of 165.77 and a price-to-book ratio of 1.82 suggesting the stock is closer to book value. The P/FCF stands at -1.76, also below market averages.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares are up 16.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lisata Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.13, suggesting 416.99% upside. Our AI forecast model points to short-term weakness (-18.59% over two weeks), a medium-term rise (105.77% over three months), and a longer-term gain (638.14% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lisata Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -18.59%, with price expected at $2.54 by May 14, 2026, within a range of $1.95 to $3.15 3-Month Outlook: Projected rise of 105.77%, reaching $6.42 by July 29, 2026, with a range of $6.31 to $6.56. 1-Year Outlook: Projected gain of 638.14%, with price at $23.03 by April 30, 2027, within a range of $23.30 to $28.55.